FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

The FDA has granted accelerated approval to dostarlimab for adult patients with stage II or III mismatch repair–deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced rectal cancer, based on strong phase 2 trial results demonstrating sustained clinical complete response and overall response rates.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it.